Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
featured
Published in Metastatic Breast Cancer

Expert Opinion / Interview · September 07, 2016

HER2 Breast Cancer and ASCO/CAP 2013 Guideline Update: A Discussion Between Drs. Lee Schwartzberg and Reshma Mahtani

Lee Schwartzberg MD, FACP
Reshma Mahtani DO
Interview with
Reshma L. Mahtani DO

 

 Save  Recommend
 Share

Additional Info

  1. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31(31): 3997-4013.
  2. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-1684.

Disclosure statements are available on the authors' profiles:

Reshma Mahtani DO

Lee Schwartzberg MD, FACP

Further Reading

Most Read This Week

Recently Updated